{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:47:50Z","timestamp":1788364070260,"version":"build-2803163510"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    A 62-year-old man was diagnosed with lung adenocarcinoma and metastases involving the bone, muscle, peritoneum, and lymph nodes. He received one cycle of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAP-2286 therapy. One month after treatment, the clinical symptoms, including chest pain, shortness of breath, and productive cough, had completely resolved. Follow-up\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAP-2286 imaging at 2 months demonstrated partial metabolic response (PERCIST 1.0), accompanied by a marked reduction in respiratory tumor marker levels. In addition, no adverse reactions were reported by the patient.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006271","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:00:21Z","timestamp":1766502021000},"page":"518-519","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["177Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma With Multiple Metastases"],"prefix":"10.1097","volume":"51","author":[{"given":"Xinyi","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, Southwest Medical University"},{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"},{"name":"Departments of Nuclear Medicine, The First People\u2019s Hospital of Mianyang, Mianyang, Sichuan, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-018-0871-7","article-title":"MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma","volume":"37","author":"Ferrer","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"R2-20260504","first-page":"147","article-title":"Role of afatinib in the treatment of advanced lung squamous cell carcinoma","volume":"9","author":"Vavala","year":"2017","journal-title":"Clin Pharmacol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2005.12.004","article-title":"Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer","volume":"52","author":"Fujiwara","year":"2006","journal-title":"Lung Cancer"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2169\/internalmedicine.9565-17","article-title":"The effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare G719X and S768I mutations","volume":"57","author":"Watanabe","year":"2018","journal-title":"Intern Med"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"R6-20260504","first-page":"285","article-title":"Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer","volume":"7","author":"Yap","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","article-title":"Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides","volume":"50","author":"Millul","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/RLU.0000000000005489","article-title":"177 Lu-FAP-2286 therapy in a case of squamous lung cancer","volume":"50","author":"Li","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-022-06048-5","article-title":"[(177)Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases","volume":"50","author":"Rao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260504","article-title":"[(177)Lu]Lu-FAP-2286 therapy in a case of gastric adenocarcinoma with peritoneal metastasis","author":"Wang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/RLU.0000000000005169","article-title":"Metastatic lung adenocarcinoma received combined 177Lu-FAP-2286 radiation therapy and targeted therapy","volume":"49","author":"Yang","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:43:04Z","timestamp":1785850984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006271"}},"subtitle":["A Promising Last-line Treatment Option"],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006271","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2025-11-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}